Booster Therapeutics is a technology company.
Booster Therapeutics has raised $15.0M across 1 funding round.
Booster Therapeutics has raised $15.0M in total across 1 funding round.
Booster Therapeutics is a Berlin-based biotechnology company developing small molecule therapeutics that activate the 20S proteasome to restore cellular protein clearance, targeting neurodegenerative diseases like Parkinson's and Alzheimer's, as well as other complex indications.[1][2][3][4] The company serves patients with proteinopathies—diseases driven by misfolded or accumulated proteins—by addressing impaired proteasome function, a core mechanism in aging-related disorders where traditional targeted degraders fall short.[2][5] It solves the problem of widespread protein dysfunction in complex diseases through its DGRADX™ platform, which enables high-throughput screening and structural optimization to generate proteasome activators, backed by a $15 million seed round led by Apollo Health Ventures and Novo Holdings in October 2024.[1][2][3]
Launched from stealth in 2024, Booster has shown early momentum with a grant from The Michael J. Fox Foundation for Parkinson's Research to advance toward a Phase 1 study, alongside building a multi-disease pipeline and a world-class team.[4][5]
Booster Therapeutics emerged in October 2024 from Apollo Health Ventures' company creation engine, founded by Dr. Diogo R. Feleciano (Co-Founder & CSO), Prof. Dr. Darci J. Trader (Scientific Co-Founder & Advisor from University of California Irvine), and Apollo Health Ventures.[1][2][3][4] The idea originated from Trader's lab work demonstrating that small molecules could directly trigger natural proteasome activation, addressing a gap in treating diseases with multiple dysfunctional proteins.[3][5] Feleciano, with deep expertise in proteasome biology, led the scientific pivot, while Apollo provided initial support to assemble the team.[1][4]
Pivotal early traction included securing $15 million in seed financing from Apollo and Novo Holdings, enabling rapid platform development and a library of activator compounds; Novo Holdings further committed operational expertise via its Seed Lab and entrepreneurs-in-residence.[2][3][6]
Booster rides the protein degradation wave in biotech, shifting from inhibition (e.g., proteasome inhibitors for cancer) to activation for age-related diseases where proteasome impairment drives protein accumulation.[2][4][5] Timing aligns with surging demand for neurodegeneration therapies—Parkinson's and Alzheimer's affect millions amid aging populations—fueled by advances in structural biology and AI-driven drug design that de-risk early discovery.[3][5] Market forces like MJFF funding and investor interest from life sciences giants (Apollo, Novo) favor proteasome modulation, as it offers a "universal surveillance" approach resilient to heterogeneous protein pathologies.[1][5]
Booster influences the ecosystem by validating proteasome activation as a new modality, potentially inspiring pipelines beyond neuro and accelerating "quality control" therapies via its open-sourced insights from platform tech.[2][4]
Booster is primed for proof-of-concept milestones, with MJFF-backed progress toward a Phase 1 Parkinson's study signaling near-term catalysts and pipeline expansion into Alzheimer's and beyond.[5] Trends like AI-accelerated screening and combo therapies with degraders will amplify its DGRADX™ edge, while backer networks drive partnerships or follow-on funding.[3][6] Its influence could evolve from pioneer to category leader if activators demonstrate broad resilience in trials, redefining treatment for protein-driven diseases and cementing proteasome power as biotech's next frontier—echoing its stealth emergence as a bold bet now gaining traction.[1][2]
Booster Therapeutics has raised $15.0M in total across 1 funding round.
Booster Therapeutics's investors include Apollo Health Ventures.
Booster Therapeutics has raised $15.0M across 1 funding round. Most recently, it raised $15.0M Seed in October 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2024 | $15.0M Seed | Apollo Health Ventures |